The Pulmonary Arterial Hypertension (Pah) Drugs Market is being driven by Growing prevalence of PAH
The Pulmonary Arterial Hypertension (Pah) Drugs Market is expected to grow at a CAGR of 6.78% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 2264.7 million. The pulmonary arteries, which facilitate the transportation of blood from the heart to the lungs, are afflicted by a rare and progressive disorder known as Pulmonary Arterial Hypertension (PAH). This condition is characterized by the narrowing or blockage of pulmonary arteries, leading to increased pressure in the pulmonary arterial system. Rising risk factors, including HIV infection, sedentary lifestyles, tobacco and alcohol consumption, and other idiopathic conditions, have contributed to the growing prevalence of PAH. Consequently, the global PAH drugs market is poised for significant growth, as market participants capitalize on the expanding patient population and the demand for effective treatments to mitigate disease progression and improve patients' quality of life.
Get more information on Pulmonary Arterial Hypertension (Pah) Drugs Market by requesting a sample report
Which Factors Are Causing a Surge in Market Growth?
The market is segmented based on Route Of Administration (Oral, Injectable, Inhalation) Action Mechanism (Prostacyclin analogs, Endothelin receptor antagonists (ERAs), Phosphodiesterase (PDE) inhibitors, Soluble guanylate cyclase stimulators (SGCSs)) Geography (North America, Europe, Asia, Rest of World (ROW)).
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
Key Features in Pulmonary Arterial Hypertension (Pah) Drugs Market Research Report
Find out which segment is leading the market by accessing the free PDF report
The Pulmonary Arterial Hypertension (PAH) Drugs Market focuses on treatments for PAH, a rare and often fatal condition affecting the pulmonary arteries and capillaries in the lungs of the geriatric population and those with heart failures. Prostacyclin, a vasodilator, targets the Cyclooxygenase (COX) pathway, while Nitric Oxide (NO) enhances vasodilation. Prostacyclin analogs and Endothelin receptor antagonists are key drugs. Obesity, cardiovascular diseases, and early diagnosis initiatives expand the patient base. Orphan drugs, clinical trials, patient advocacy efforts, and vaccine projects aim for improved patient outcomes and quality of life amidst challenges like transportation of drugs and viral outbreaks.
The Pulmonary Arterial Hypertension (PAH) drugs market is a significant segment within the larger global pharmaceuticals market. This sector focuses on research and development, as well as production of both generic and non-generic medications. Key therapeutic areas for PAH drugs include those targeting the Prostacyclin and Cyclooxygenase (COX) pathways, as well as Nitric Oxide (NO) modulators. As the geriatric population continues to expand, driven by increasing life expectancy, the demand for PAH treatments is expected to rise. By 2050, approximately one-quarter of the US population, and by 2030 in Europe, will be over the age of 60. This demographic shift will significantly impact the healthcare market, including the PAH drugs sector.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
